Neuralgia News and Research

RSS
Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.
Takeda receives FDA approval for VELCADE sNDA to treat MM

Takeda receives FDA approval for VELCADE sNDA to treat MM

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

Laser Med Center receives FDA approval for device to treat Trigeminal Neuralgia

Laser Med Center receives FDA approval for device to treat Trigeminal Neuralgia

Aestus to develop ATx09-002 for treatment of neuropathic pain

Aestus to develop ATx09-002 for treatment of neuropathic pain

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Microvascular compression syndrome may cause Parkinson's

Microvascular compression syndrome may cause Parkinson's

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex secures AU$6.25 million in expanded Series B funding

Santarus, Depomed enter new commercialization agreement for GLUMETZA

Santarus, Depomed enter new commercialization agreement for GLUMETZA

American Shared Hospital Services first half 2011 revenues increase 4.0% to $8,573,000

American Shared Hospital Services first half 2011 revenues increase 4.0% to $8,573,000

Inhibitex second quarter net loss decreases to $5.3 million

Inhibitex second quarter net loss decreases to $5.3 million

Vampire bats can smell blood-rich prey: Study

Vampire bats can smell blood-rich prey: Study

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Ironwood licenses worldwide rights to Depomed's Acuform drug delivery technology

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Skin cell-derived CGRP-beta may cause chronic pain

Skin cell-derived CGRP-beta may cause chronic pain

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents VELCADE Phase III trial data in multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

Millennium presents three studies in relapsed multiple myeloma at IMW meeting

NeurogesX first quarter revenue is $3.2 million for 2011

NeurogesX first quarter revenue is $3.2 million for 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium submits two VELCADE sNDAs to FDA